Pharmacology

Cyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flareCyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flare

Cyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flareCyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flare

Cyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flareCyclosporin A, CyA, ulcerative colitis, Cambridge University Hospitals National Health Service Foundation Trust, United Kingdom, colectomy, intravenous steroids, steroidrefractory flare

elderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scaleelderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scale

elderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scaleelderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scale

elderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scaleelderly patients, advanced cancer, chemotherapy, life-extending treatment, life-enhancing treatment, National Federation of Centers Fighting Cancer, Paris, 5-Fluorouracil, 5-FU, metastatic colorectal cancer, mCRC, capecitabine-oxaliplatin, XELOX, capecitabine, oxaliplatin, Katz Activities of Daily Living scale, ADL scale

bacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infectionbacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infection

bacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infectionbacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infection

bacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infectionbacterial vaginosis, BV, birth complications, sexualy transmitted diseases, STDs, tinidazole, metronidazole, yeast infection

chronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activitychronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activity

chronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activitychronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activity

chronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activitychronic rhinosinusitis, CRS, nasal polyposis, nasal blockage, facial pain, hyposmia, oral steroids, topical steroids, oral prednisolone, fluticasone propionate nasal drops, fluticasone propionate nasal spray, adrenal suppression, osteoblast activity

propofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-freepropofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-free

propofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-freepropofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-free

propofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-freepropofol, postoperative infection, nosocomial infection, contamination, blood glucose level, daily caloric intake, insulin therapy, insulin, intensive care unit, ICU, ethylenediaminetetraacetic acide, EDTA, lipid-free

selective serotonin reuptake inhibitor, SSRI, tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapyselective serotonin reuptake inhibitor, SSRI,tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapy

selective serotonin reuptake inhibitor, SSRI, tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapyselective serotonin reuptake inhibitor, SSRI,tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapy

selective serotonin reuptake inhibitor, SSRI, tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapyselective serotonin reuptake inhibitor, SSRI,tricyclic antidepressants, myocardial infarcation, MI, depression, antidepressants, mortality, pharmacotherapy

acute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemiaacute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemia

acute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemiaacute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemia

acute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemiaacute coronary syndrome, ACS, intensive lipid-lowering therapy, low-density lipoprotein, statin therapy, Get With the Guidelines, American Heart Association, stains, myocardial ischemia

amidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast mediumamidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast medium

amidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast mediumamidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast medium

amidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast mediumamidotrizoate, cancer treatment, constipation, dehydration, metabolic change, concurrent medication, bowel movement, senna, lactulose, diarrhea, enema, hyperosmolar water-soluble contrast medium

opioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant painopioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant pain

opioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant painopioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant pain

opioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant painopioids, chronic pain, tertiary-care patient, substance misuse, pain relief, exercise, self-reported acute relief, nonmalignant pain

gout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricasegout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricase

gout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricasegout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricase

gout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricasegout, contraindications, acute gout, chronic gout, prednisone, colchicine, NSAIDs, renal failure, colchicine toxicity, nonpurine xanthine oxidase inhibitor febuxostat, pegylated uricase